Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any case of serious hypoglycemia or other serious or unexpected side effects in patients receiving repaglinide and clopidogrel should be reported to the respective manufacturer of repaglinide prescribed as indicated below or to Health Canada.
GlucoNorm® (repaglinide)
Novo Nordisk Canada Inc.
300-2680 Skymark Avenue
Mississauga, ON, L4W 5L6
Telephone: 1-800-465-4334
Email: nnci-drugsafety@novonordisk.com ACT-Repaglinide (repaglinide)
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, ON, L5N 6J5
Telephone: 866-254-6111
APO-Repaglinide (repaglinide)
Apotex Inc.
150 Signet Drive
Toronto, ON, M9L 1T9
Telephone: 1-800-667-4708 or 416-401-7780
Fax: 1-866-429-9133 or 416-401-3819
Email: drugsafety@apotex.com pms-REPAGLINIDE (repaglinide)
Pharmascience Inc.
6111, Avenue Royalmount, Suite 100
Montreal, PQ, H4P 2T4
Telephone: 1-888-550-6060
Fax: 1-514-340-0164
Email: medinfo@scientificaffairs.ca Repaglinide (repaglinide)
Pro Doc Ltée
2925 Boulevard Industriel
Laval, PQ, H7L 3W9
Telephone: 1 800 361-8559
Fax: 450-668-0816
Email: jdeschenes@prodoc.qc.ca Sandoz Repaglinide (repaglinide)
Sandoz Canada Inc.
145 Jules-Léger Street
Boucherville, PQ, J4B 7K8
Telephone : 1-800-343-8839 ext : 4636
Fax: 1-888-243-6221
Email: medinfo@sandoz.com AURO-Repaglinide (repaglinide)
Auro Pharma Inc.
3700 Steeles Avenue West, Suite 402
Woodbridge ON, L4L 8K8
Tel: 905-856-8063 ext 223
Email: rana.harb@aurobindo.com To correct your mailing address or fax number, contact the manufacturer(s). You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
-
Calling toll-free at 1-866-234-2345; or
-
Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
For other health product inquiries related to this communication, contact Health Canada at:
Marketed Health Products Directorate
E-mail:
mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Original signed by Dr. Mohamed Eid
Vice President, Clinical, Medical and Regulatory
Novo Nordisk Canada Inc.
Kent Major
Vice President, Regulatory Affairs
Actavis Pharma Company
Dr. Colin D’Cunha
Director Global Medical Affairs
Apotex Inc.
Ms. Rana Harb
Manager Regulatory Affairs
Auro Pharma Inc.
Len Neirinck, Ph.D.
Vice-president and Chief Scientific Officer, Scientific Affairs
Pharmascience Inc.
Jovette Deschênes,
Director, QC/QA and Regulatory Affairs
Pro Doc Ltée
Len Arsenault
Vice President, Scientific Affairs
Sandoz Canada Inc.
References
1. Tornio A, Filppula AM, Kailari O et al. Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions. Clin Pharmacol Ther 2014 Oct,96(4):498-507